In this context, it is noteworthy that we recently determined that the pharmacokinetic profile of sorafenib and its glucuronide metabolite in patients with cancer is affected by concurrent usage of micafungin, posaconazole, and voriconazole by a mechanism that involves modulation of the OATP1B1 function [47]. Here, SLCO1B1 is linked to cancer.